Eli Casdin
Founder and CIO at CASDIN CAPITAL
Investor
Deal Bio
Awards
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.
Expertise (46)
Key Relationships
Sort
Verana Health
Casdin Capital
£76m
5 dealmakers
INSITRO
Alexandria Venture Investments
£116m
38 dealmakers
Kronos Bio
Perceptive Advisors
£118m
18 dealmakers
Lyra Health
Addition Ventures
£83m
10 dealmakers
Dna Script
Danaher Corporation
£75m
11 dealmakers
Thrive Earlier Detection Corp
Exact Sciences
£1,651m
66 dealmakers
4d Molecular Therapeutics
Mirae Asset Financial Group
£56m
Neurogene
£85m
14 dealmakers
Nautilus Biotechnology
Arya Sciences Acquisition Corp Iii
£654m
44 dealmakers
SEMA4
T. Rowe Price Group
£1,450m
BLACKROCK
£287m
27 dealmakers
ABSCI
£90m
SOMALOGIC
Janus Henderson Investors
£891m
63 dealmakers
Century Therapeutics
Fidelity Management & Research Company
£115m
24 dealmakers
Tango Therapeutics
Cormorant Asset Management
£257m
32 dealmakers
C2i Genomics
The Mark Foundation For Cancer Research
£72m
13 dealmakers
Affinia Therapeutics
£80m
15 dealmakers
INIVATA
NEOGENOMICS
£281m
41 dealmakers
Dyno Therapeutics
Gv (google Ventures)
£71m
Ginkgo Bioworks
Baillie Gifford & Co
£10,641m
107 dealmakers
Leyden Labs
£34m
19 dealmakers
Nikang Therapeutics
Surveyor Capital
£141m
29 dealmakers
LETSGETCHECKED
Transformation Capital Partners
£105m
12 dealmakers
Mnemo Therapeutics
Emerson Collective
£63m
6 dealmakers
Prime Medicine
£227m
17 dealmakers
T-KNIFE
Caas Capital Management
£79m
EQRX
Bvf Partners
£2,622m
53 dealmakers
Avidity Partners
£144m
26 dealmakers
SHOUTI
20 dealmakers
£119m
28 dealmakers
Sonoma Biotherapeutics
£190m
Chroma Medicine
Atlas Venture
£93m
EUREKARE
£148m
Maze Therapeutics
Driehaus Capital
£139m
FLUIDIGM
£184m
23 dealmakers
Ventus Therapeutics
Andreessen Horowitz
£103m
Moma Therapeutics
Rock Springs Capital
£121m
INVETX
F-prime Capital
£49m
Celsius Therapeutics
Third Rock Ventures
£68m
3 dealmakers
IDRX
£99m
7 dealmakers
Komodo Health
Iconiq Capital
£192m
9 dealmakers
TRIALSPARK
Sequoia Capital
£138m
ASIMOV
Kdt Ventures
£145m
8 dealmakers
Arch Venture Partners
£111m
SEPTERNA
Ra Capital Management
Patch Biosciences
value n/a
25 dealmakers